PuSH - Publication Server of Helmholtz Zentrum München: Phenolic acids from <em>Anisopus</em> mannii modulates phosphofructokinase 1 to improve glycemic control in patients with type 2 diabetes: A double-blind, randomized, clinical trial.

Information

Clues to quality of journals

Open Access Policy of Helmholtz Association 2016

CC Licencences

Publication Metrics

Navigation

Home

Deutsch

EVA: Electronic Publishing

New EVA Application

Research

Advanced Search

Browse by ...

... HMGU-Authors/Consortia

... Organizational Structure

... Journal

... Publication Type

... Research Data

... Arbeitsgruppen

... Publication Year

Publication overview

Statistics

Statistics (last 5 years)

OA Publications

Publish

Submit Publication

Import publication from...

...EVA

Report missing publication

Highlights

Support & Contact

Contact persons

Help

Data protection

Helmholtz Open Science

JANE Journal Estimator

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Amadi, P.U.* ; Osuoha, J.O.* ; Ekweogu, C.N.* ; Jarad, S.J.* ; Efiong, E.E. ; Odika, P.C.* ; Ejiofor, C.* ; Aloy-Amadi, O.* ; Gill, G.S.* ; Adumekwe, C.W.* ; Gaowa, A.* ; Zhang, D.* ; de Courten, B.* ; Agomuo, E.N.*

Phenolic acids from Anisopus mannii modulates phosphofructokinase 1 to improve glycemic control in patients with type 2 diabetes: A double-blind, randomized, clinical trial.

Pharmacol. Res. 212:107602 (2025)

Publ. Version/Full Text

Research data

DOI

PMC

	Open Access Hybrid

Abstract
Metrics
Extra information

Phenolic acid-rich fraction from Anisopus mannii (PhAM) contains abundance of ferulic acid, gallic acid, protocatechuic acid, and syringic acid. Among other glycolytic enzymes, in vitro, PhAM counteracted the binding of sodium orthovanadate to phosphofructokinase 1 (PFK-1), improving its activities. In a rat model of diet-induced diabetes, PhAM monotherapy reduced HbA1c by an average of 0.63% and fasting plasma glucose by 25mg/dl. This herb rescued β-cells from streptozotocin-mediated destruction, thereby improving glycemic control. Supported by the preclinical trial, eighty-five patients with type 2 diabetes (T2D) receiving first-line medications were enrolled in a double-blind, randomized, placebo-controlled trial with a 90% power level. Patients were randomized into a placebo group or either of the following two treatment groups: oral administration of 12mg or 20mg/kg body weight of PhAM once every 48h for 6 months. Both treatments were well tolerated. At the endpoint, more than 70% of patients achieved a 0.5 - 2.0 decrease in HbA1c levels and a >20mg/dl decrease in fasting blood glucose, meeting the pre-specified primary outcome. 66% of patients treated with 20mg PhAM achieved the < 7% HbA1c and HOMA-IR of > 1.0 goal. respectively. Our study shows that PhAM can supplement first-line medications to achieve target glycemic control within 6 months. Pan African Clinical Trial Registration number: PACTR202206531545729.

Impact Factor

Scopus SNIP

Altmetric

10.500

0.000